Cediranib
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Elimination half-life | 12 to 35 hours |
| Identifiers | |
| |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.196.628 |
| Chemical and physical data | |
| Formula | C25H27FN4O3 |
| Molar mass | 450.5 g/mol g·mol−1 |
AZD2171 (tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases. It is being developed by AstraZeneca as a possible chemotherapeutic agent for oral administration.
As of 2007, it is undergoing Phase I clinical trials for the treatment of non-small cell lung cancer and colorectal cancer in adults, as well as tumors of the central nervous system in children.
Further reading
- Wedge S, Kendrew J, Hennequin L; et al. (2005). "AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer". Cancer Res. 65 (10): 4389–400. PMID 15899831.
{{cite journal}}: Explicit use of et al. in:|author=(help)CS1 maint: multiple names: authors list (link)
External links
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |